SD 169 (indole-5-carboxamide): Selective ATP-Competitive p38 MAPK Inhibitor for Precision Research

Executive Summary: SD 169 (indole-5-carboxamide) is a well-characterized ATP-competitive inhibitor targeting p38α and p38β MAP kinases, with documented selectivity and ≥97% purity (APExBIO, product page). It modulates p38 MAPK-dependent pathways, reducing inflammatory cytokine production and T cell activation in preclinical models of type 1 diabetes (Stadnicki et al., 2024). The compound’s mechanism includes direct kinase inhibition and enhanced phosphatase-mediated dephosphorylation. SD 169 also demonstrates neuroprotective effects by promoting axonal regeneration. It can be integrated into apoptosis, autophagy, and inflammatory response assays, with robust solubility and storage parameters ensuring experimental reproducibility.

Biological Rationale

Reversible phosphorylation by protein kinases and phosphatases regulates critical cellular processes, including cell proliferation, differentiation, apoptosis, and inflammatory responses (Stadnicki et al., 2024). The p38 mitogen-activated protein kinases (MAPKs), particularly p38α (MAPK14) and p38β, mediate cellular responses to stress stimuli such as cytokines, heat shock, UV irradiation, and osmotic shock. Dysregulation of p38 MAPK signaling is implicated in chronic inflammation, autoimmune conditions, and neurodegenerative diseases. Selective inhibition of p38α/β provides a targeted approach to modulate stress-induced signal transduction without broadly suppressing related MAPK pathways. SD 169 (indole-5-carboxamide) is designed to achieve this specificity, enabling researchers to dissect p38-driven mechanisms in disease and homeostasis (erk12.com article).

Mechanism of Action of SD 169 (indole-5-carboxamide)

SD 169 is a small-molecule inhibitor with the chemical formula C9H8N2O and a molecular weight of 160.2 Da. It binds the ATP-binding pocket of p38α and p38β MAPKs, exhibiting high selectivity and competitive inhibition. Structural studies indicate that SD 169 stabilizes p38α in an inactive, 'flipped' activation loop conformation, rendering the phospho-threonine site more accessible to the serine/threonine phosphatase WIP1 (Stadnicki et al., 2024). This dual-action—active site blockade and increased dephosphorylation—results in robust downregulation of p38 MAPK activity. The compound also modulates downstream events, including repression of inflammatory cytokine production (e.g., TNF-α, IL-6), reduced T cell infiltration in pancreatic islets, and preservation of β-cell mass in diabetes models.

• ATP-competitive inhibition: SD 169 binds the kinase's ATP site, blocking substrate phosphorylation.
• Activation loop stabilization: Induces a conformation that accelerates phosphatase access and dephosphorylation.
• Downstream effects: Reduces inflammatory cytokine signaling, T cell activation, and apoptosis in stress models.

This mechanism extends beyond standard kinase inhibition by leveraging conformational control to boost selectivity and pathway suppression (tpca-1.com article; contrast: this article details dual-action mechanism with recent structural data).

Evidence & Benchmarks

• SD 169 inhibits p38α and p38β MAPKs with high selectivity, with no significant off-target inhibition of ERK or JNK at ≤10 μM (Stadnicki et al., 2024, DOI).
• In NOD mouse models of type 1 diabetes, SD 169 at 5 mg/kg/day (i.p., 21 days) reduces intrapancreatic T cell infiltration and preserves β-cell mass, as measured by immunohistochemistry (DOI).
• SD 169 decreases expression of p38 and HSP60 proteins in T cells isolated from pancreatic islets (Western blot analysis, n=6, p<0.01; DOI).
• Compound enhances axonal regeneration in sciatic nerve crush injury models, promoting Schwann cell signaling and reducing TNF-α mediated Schwann cell apoptosis (in vivo: 10 mg/kg, 14 days; DOI).
• SD 169 is ≥97% pure (HPLC analysis; APExBIO, product page).
• Solubility parameters: 1.4 mg/ml in ethanol, 5 mg/ml in DMSO, 16 mg/ml in DMF at 20°C (APExBIO, product page).

For deeper bench-to-bedside context, see this article (contrast: this article integrates new conformational insights from 2024 structural biology).

Applications, Limits & Misconceptions

SD 169 is used in research models of:

• Type 1 diabetes: To study T cell-mediated β-cell destruction and cytokine modulation.
• Neuroregeneration: To investigate axonal regrowth and Schwann cell survival post-injury.
• Inflammatory disease: To probe cytokine production and MAPK pathway cross-talk.
• Apoptosis and autophagy assays: For dissecting stress-activated kinase networks.

SD 169 enables high-fidelity modulation of p38 MAPK signaling, allowing for dissection of pathway-specific effects in complex disease models. Its dual-action mechanism offers improved selectivity compared to conventional inhibitors (ay-9944.com article; contrast: this article provides explicit solubility, stability, and workflow guidance for practitioners).

Common Pitfalls or Misconceptions

• Not a general MAPK inhibitor: SD 169 does not significantly inhibit ERK1/2 or JNK MAPKs at recommended concentrations (≤10 μM).
• Limited in vivo pharmacokinetics: The compound is primarily validated in preclinical rodent models; human PK/PD data are lacking.
• Stability constraints: SD 169 is stable at -20°C; solutions should be used within short-term windows to prevent degradation.
• Not suitable for chronic human exposure: For research use only; not approved for clinical or diagnostic applications.
• Potential solvent interference: Solubility in ethanol, DMSO, or DMF must be matched to assay system to prevent non-specific effects.

Workflow Integration & Parameters

SD 169 (APExBIO, C5850) is delivered as a crystalline solid, with ≥97% purity confirmed by HPLC. It is soluble up to 1.4 mg/ml in ethanol, 5 mg/ml in DMSO, and 16 mg/ml in dimethyl formamide at 20°C. For optimal stability, store at -20°C; use freshly prepared solutions for best results. The compound is shipped with blue ice for small molecules. When preparing assay stocks, filter-sterilize solutions if required, and avoid repeated freeze-thaw cycles. For in vitro assays, recommended working concentrations are 0.1–10 μM depending on cell type and endpoint. For in vivo studies (e.g., NOD mouse model), dosing regimens of 5–10 mg/kg/day (i.p.) have been validated for 2–3 week studies (DOI).

For further product details and ordering, see the SD 169 (indole-5-carboxamide) product page.

Conclusion & Outlook

SD 169 (indole-5-carboxamide) offers researchers a powerful, selective ATP-competitive p38α and p38β inhibitor, supporting advanced studies in inflammation, type 1 diabetes, neuroregeneration, and stress response pathways. Its dual-action mechanism, involving both kinase inhibition and enhanced phosphatase-mediated dephosphorylation, sets a new benchmark for specificity and pathway suppression. APExBIO’s rigorous quality control and comprehensive documentation ensure reproducibility and reliability for experimental workflows. While SD 169 is not a pan-MAPK inhibitor and lacks clinical approval, it remains a cornerstone reagent for dissecting p38 MAPK biology in preclinical systems. Ongoing structural and pharmacological insights are expected to further refine its application in next-generation kinase pathway research.